Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Pipeline Analysis 2017 - Research and Markets

Research and Markets
Posted on: 03 Aug 17

The "Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Pipeline Analysis 2017" report has been added to Research and Markets' offering.

Disease Overview

Chronic obstructive pulmonary disease (COPD) is a broad term used for progression of various diseases affecting the lungs such as, chronic bronchitis, some forms of bronchiectasis, emphysema and refractory (non-reversible) asthma.

Breathlessness and coughing are few of the early symptoms that induce the hypothesis of having COPD, but some people also consider these symptoms as the signs of aging. In no time, these ailments come under severe progression and reveal the rising of other associated diseases.

The primary diagnosis of COPD is spirometry, which is the most common form of pulmonary function test that includes measurement of volume and flow of inhaled and exhaled air in the lungs. Therefore, analyzing the breathing pattern may assess the complications involved with the lungs.

COPD is a disease that develops over the years and the associated symptoms are wheezing, tightness in chest, increased breathlessness and frequent coughing.

In COPD, the lungs cells lose their quality of elasticity, most of the air sacs are destroyed, and the walls of the airways become thick and inflamed and in some cases also become clogged by mucus.

Chronic bronchitis and emphysema are the two-main conditions that progress throughout the period of progression of the disease, due to which air sacs lose their shape and become floppy.

The destruction of walls of air sacs leads to the enlargement of these sacs, and they no longer remain in their normal shape, which further leads to reduction in the amount of gas exchange in the lungs.

Key Players are: (developing drugs for the treatment of COPD)

  • Chiesi Farmaceutici S.p.A.,
  • AstraZeneca plc,
  • GlaxoSmithKline plc
  • and others.

Key Topics Covered:

1. Research Background

2. Research Methodology

3. Executive Summary

4. Pipeline Outlook

5. Chronic Obstructive Pulmonary Disease Therapeutics Pipeline Analysis By Phase (2017)

6 Competitive Landscape

7 Company Profiles

For more information about this report visit

View source version on

Business Wire

Last updated on: 03/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.